Literature DB >> 19746217

A case of organizing pneumonia associated with rituximab.

Chi Hoon Maeng1, Sang Ouk Chin, Byung Hyuk Yang, Si-young Kim, Hwi-Joong Youn, Kyung Sam Cho, Sun Kyung Baek, Sun Lee.   

Abstract

Rituximab is a human/murine chimeric anti-CD20 monoclonal antibody used to treat CD20-positive B-cell non-Hodgkin's lymphoma (NHL). Although most of the adverse effects associated with rituximab are usually reversible and temporary infusion-related reactions, including fever, chills, flushing and skin reactions, there are several reports of pulmonary events after long-term administration of rituximab. We present a case of asymptomatic nodular organizing pneumonia occurring during rituximab-based chemotherapy in a patient with non-Hodgkin's lymphoma.

Entities:  

Keywords:  Non-Hodgkin's lymphoma; Organizing pneumonia; Rituximab

Year:  2007        PMID： 19746217      PMCID： PMC2739322          DOI： 10.4143/crt.2007.39.2.88

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN： 1598-2998            Impact factor:   4.679


  15 in total

1.  Solitary nodular form of bronchiolitis obliterans organizing pneumonia.

Authors:  Leonardo Astudillo; Guillaume Martin-Blondel; Nicolas Sans; Ghislaine Dhaste; Bertrand Couret; Elisabeth Arlet-Suau
Journal:  Am J Med       Date:  2004-12-01       Impact factor: 4.965

2.  Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim.

Authors:  C Macartney; E Burke; S Elborn; N Magee; P Noone; I Gleadhill; D Allen; P Kettle; M Drake
Journal:  Leuk Lymphoma       Date:  2005-10

Review 3.  Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.

Authors:  M Mian; C Rass; G Hutarew; B Kofler; M Fiegl; R Greil
Journal:  Leuk Lymphoma       Date:  2006-08

4.  Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting.

Authors:  Laurie H Sehn; Jane Donaldson; Allison Filewich; Catherine Fitzgerald; Karamjit K Gill; Nancy Runzer; Barb Searle; Sheila Souliere; John J Spinelli; Judy Sutherland; Joseph M Connors
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

5.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

6.  Idiopathic bronchiolitis obliterans organizing pneumonia. Definition of characteristic clinical profiles in a series of 16 patients.

Authors:  J F Cordier; R Loire; J Brune
Journal:  Chest       Date:  1989-11       Impact factor: 9.410

Review 7.  Bronchiolitis obliterans organizing pneumonia.

Authors:  G R Epler
Journal:  Arch Intern Med       Date:  2001-01-22

8.  Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.

Authors:  Ercole Brusamolino; Chiara Rusconi; Luigi Montalbetti; Livio Gargantini; Lilj Uziel; Graziella Pinotti; Sergio Fava; Luigi Rigacci; Guido Pagnucco; Cristiana Pascutto; Enrica Morra; Mario Lazzarino
Journal:  Haematologica       Date:  2006-03-15       Impact factor: 9.941

Review 9.  B cell non-Hodgkin's lymphoma: rituximab safety experience.

Authors:  Ann Mohrbacher
Journal:  Arthritis Res Ther       Date:  2005-05-18       Impact factor: 5.156

Review 10.  Cryptogenic organizing pneumonia.

Authors:  Jean-François Cordier
Journal:  Clin Chest Med       Date:  2004-12       Impact factor: 2.878
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.